PulseAugur
EN
LIVE 14:17:01

Billy Evans' laser-based diagnostics startup Haemanthus faces scrutiny

Billy Evans, former partner of Theranos founder Elizabeth Holmes, is leading a startup called Haemanthus that aims to use lasers for disease detection. The company has reportedly raised up to $20 million and secured at least one patent for its technology, which utilizes Raman spectroscopy. However, Haemanthus has yet to publicly release a product or present data demonstrating its effectiveness, and it has lost its chief technology officer. AI

IMPACT Potential for AI-driven diagnostics, but current lack of product and data raises questions about its viability.

RANK_REASON Article discusses a startup with patents and investors but no product, drawing parallels to Theranos.

Read on Fortune →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Billy Evans' laser-based diagnostics startup Haemanthus faces scrutiny

How we ranked this

Signal score
22 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Article discusses a startup with patents and investors but no product, drawing parallels to Theranos.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Fortune TIER_1 English(EN) · Bilin Lin ·

    Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product

    As You Can See Everything turns Billy Evans into the year’s most unlikely documentary villain, his Austin startup Haemanthus faces a simple question: What has it built?